Elanco/$ELAN
1D1W1MYTD1Y5YMAX
Capital at risk
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
- Ticker
- $ELAN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 9,650
- Headquarters
- Indianapolis, United States
- Website
- www.elanco.com
Elanco Metrics
BasicAdvanced
$12B
-
-$0.41
1.69
-
Price and volume
Market cap
$12B
Beta
1.69
52-week high
$27.98
52-week low
$18.22
Average daily volume
7.2M
Financial strength
Current ratio
2.05
Quick ratio
0.908
Long term debt to equity
0.631
Total debt to equity
0.643
Interest coverage (TTM)
1.25%
Profitability
EBITDA (TTM)
1,007
Gross margin (TTM)
55.36%
Net profit margin (TTM)
-3.96%
Operating margin (TTM)
6.77%
Effective tax rate (TTM)
-19.88%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
1.56%
Return on equity (TTM)
-2.98%
Valuation
Price to revenue (TTM)
2.295
Price to book
1.76
Price to tangible book (TTM)
-7.92
Price to free cash flow (TTM)
30.403
Free cash flow yield (TTM)
3.29%
Free cash flow per share (TTM)
0.761
Growth
Revenue change (TTM)
11.95%
Earnings per share change (TTM)
-146.35%
3-year revenue growth (CAGR)
5.10%
3-year earnings per share growth (CAGR)
20.73%
What the Analysts think about Elanco
Analyst ratings (Buy, Hold, Sell) for Elanco stock.
Analyst projections of the future price of Elanco stock.
Bulls say / Bears say
Q2 2026 results beat expectations, raising full-year adjusted EPS guidance to $1.10–$1.16 and reducing net leverage to 3.1× EBITDA from 3.6× at end-2025 (PR Newswire, SEC)
Launched Befrena™ in May 2026, its second dermatology monoclonal antibody, expanding its presence in the $1.3 billion U.S. canine dermatology market and complementing Zenrelia™ (PR Newswire)
Fitch Ratings upgraded Elanco’s long-term issuer default rating to BB+ from BB in August 2026, citing balance-sheet deleveraging and improved competitive positioning in pet health (Investing.com)
Despite improvement, net leverage at 3.1× adjusted EBITDA remains above management’s lower‐end target of 3.0×, constraining financial flexibility amid economic uncertainty (SEC)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Elanco Financial Performance
Revenues and expenses
Elanco Earnings Performance
Company profitability
Upcoming events
No upcoming events
Elanco News
AllArticlesVideos
Funds containing Elanco
AllUSDGBPEUR
Fund name | Fund size | $ELAN weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.33% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.33% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.22% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.22% |
iShares MSCI World Small Cap$WSML | $9B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.